Supportive Care in Oncology | Access and Reimbursement | US | 2017

The treatment of both solid and hematological cancers is associated with a wide range of serious side effects, including chemotherapy-associated neutropenia and anemia, nausea and vomiting, and oral mucositis. In addition to some of these adverse events being life-threatening, they have a significant detrimental impact on patients’ quality of life and often require dose delays, dose reductions, or cessation of cancer treatment, thereby compromising outcomes. As a result, the optimal treatment of chemotherapy-related side effects using supportive care therapies is an integral part of good cancer patient care.  Clinical factors play a critical role in supportive therapy choice, but payer restrictions also shape prescribing decisions. Emerging therapy and biosimilar pricing will have a significant impact on MCO coverage in commercial plans in the near future. A significantly lower price than the standard of care features prominently among the top most important attributes for development of new supportive care therapies, both according to surveyed payers and physicians.

Login to access report

launch Related Market Assessment Reports